Search Results - "Gomez-Roca, C"

Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages.

Authors: Gomez-Roca, C A Italiano, A Tourneau, C Le et al.

Source: Annals of Oncology. Aug2019, Vol. 30 Issue 8, p1381-1392. 12p. 2 Charts, 5 Graphs.

Sequential research-related biopsies in phase I trials: acceptance, feasibility and safety.

Authors: Gomez-Roca, C. A. Lacroix, L. Massard, C. et al.

Source: Annals of Oncology. May2012, Vol. 23 Issue 5, p1301-1306. 6p. 1 Black and White Photograph, 2 Diagrams, 1 Chart, 1 Graph.

LBA41 LEAP-005: Phase II study of lenvatinib (len) plus pembrolizumab (pembro) in patients (pts) with previously treated advanced solid tumours.

Authors: Lwin, Z. Gomez-Roca, C. Saada-Bouzid, E. et al.

Source: Annals of Oncology. 2020 Supplement 4, Vol. 31, pS1170-S1170. 1p.

ESMO-Magnitude of Clinical Benefit Scale version 2.0 (ESMO-MCBS v2.0).

Authors: Cherny, N.I. Oosting, S.F. Dafni, U. et al.

Source: Annals of Oncology. Aug2025, Vol. 36 Issue 8, p866-908. 43p.

443TiPFirst-in-human trial design for W0101: A first-in-class antibody-drug conjugate targeting IGF-1R and identification of the target patient population.

Authors: Gomez-Roca, C A Garralda-Cabanas, E Cruzalegui, F et al.

Source: Annals of Oncology. 2018 Supplement, Vol. 29, pN.PAG-N.PAG. 1p.

Prise en charge des patients atteints de métastases cérébrales de mélanome.

Authors: Modesto, A. Chira, C. Sol, J.-C. et al.

Source: Cancer Radiothérapie. Apr2019, Vol. 23 Issue 2, p147-150. 4p.

Oral lichenoid reactions associated with anti- PD-1/ PD-L1 therapies: clinicopathological findings.

Authors: Sibaud, V. Eid, C. Belum, V.R. et al.

Source: Journal of the European Academy of Dermatology & Venereology. Oct2017, Vol. 31 Issue 10, pe464-e469. 5p.

Phase I study of temsirolimus in combination with cetuximab in patients with advanced solid tumours.

Authors: Hollebecque, A. Bahleda, R. Faivre, L. et al.

Source: European Journal of Cancer. Aug2017, Vol. 81, p81-89. 9p.

Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal.

Authors: Ott, P. A. Piha-Paul, S. A. Munster, P. et al.

Source: Annals of Oncology. May2017, Vol. 28 Issue 5, p1036-1041. 6p. 3 Charts, 1 Graph.

Debio0932, a second-generation oral heat shock protein (HSP) inhibitor, in patients with advanced cancer--results of a first-in-man dose-escalation study with a fixed-dose extension phase.

Authors: Isambert, N. Delord, J.-P. Soria, J.-C. et al.

Source: Annals of Oncology. May2015, Vol. 26 Issue 5, p1005-1011. 7p. 1 Diagram, 2 Charts, 1 Graph.

Outcome of patients with sarcoma and other mesenchymal tumours participating in phase I trials: a subset analysis of a European Phase I database.

Authors: Cassier, P. A. Polivka, V. Judson, I. et al.

Source: Annals of Oncology. Jun2014, Vol. 25 Issue 6, p1222-1228. 7p.

170TiP A phase I study to characterize the safety and tolerability of MP0317, a tumor targeting FAP dependent CD40 agonist DARPin®, in patients with relapsed/refractory solid tumors.

Authors: Jeger, S. Schönborn-Kellenberger, O. De Winter, H. et al.

Source: Annals of Oncology. 2021 Supplement 7, Vol. 32, pS1456-S1457. 2p.

EE608 Cost Effectiveness Analysis of a Large (Foundation Medicine) Versus a Home-Based Medium Gene Panel for Exome Sequencing: Results of the Profiler 02 Randomized Clinical Trial.

Authors: Perrier, L Tredan, O Morelle, M et al.

Source: Value in Health. 2022 Suppl, Vol. 25 Issue 12, pS175-S175. 1p.

Oral squamous cell carcinoma and hyperkeratotic lesions with BRAF inhibitors.

Authors: Vigarios, E. Lamant, L. Delord, J.P. et al.

Source: British Journal of Dermatology. Jun2015, Vol. 172 Issue 6, p1680-1682. 3p.

P-139 A phase 2 multicohort study (LEAP-005) of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors: Pancreatic cancer cohort.

Authors: Chung, H. Villanueva, L. Graham, D. et al.

Source: Annals of Oncology. 2021 Supplement 3, Vol. 32, pS146-S146. 1p.

Radiothérapie et immunothérapie anti-PD-1 concomitante chez les patients atteints d’un mélanome métastatique : données préliminaires d’efficacité et de tolérance.

Authors: Aboudaram, A. Chira, C. Delannes, M. et al.

Source: Cancer Radiothérapie. Oct2017, Vol. 21 Issue 6/7, p721-722. 2p.

898PVOTRAGE study pazopanib in a population of "frail" elderly patients after geriatric assessment: A phase I study with geriatric criteria.

Authors: Mourey, L Ravaud, A Digue, L et al.

Source: Annals of Oncology. 2018 Supplement, Vol. 29, pN.PAG-N.PAG. 1p.

412PDClinical activity, safety, and PK/PD from a phase I study of RO6874281, a fibroblast activation protein (FAP) targeted interleukin-2 variant (IL-2v).

Authors: Melero, I Alvarez, E Castanon Mau-Sorensen, M et al.

Source: Annals of Oncology. 2018 Supplement, Vol. 29, pN.PAG-N.PAG. 1p.

SP-0598: Cilengitide in continuous infusion with radio-chemotherapy in stage III NSCLC: A phase I clinical trial.

Authors: Cohen-Jonathan Moyal, E. Massabeau, C. Filleron, T. et al.

Source: Radiotherapy & Oncology. 2014 Supplement, Vol. 115, pS291-S291. 1p.

O8:3 TARGETING TUMOR-ASSOCIATED MACROPHAGES IN CANCER PATIENTS

Authors: Rüttinger, D. Cassier, P. Cannarile, M. et al.

Source: Annals of Oncology. 2015 Supplement, Vol. 26, pii12-ii12. 1p.